Gaithersburg, MD, May 17, 2016 – MaxCyte® Inc., the developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to collaborate in the evaluation of the MaxCyte Scalable Transfection Platform for the rapid development of cell-based proteins such as vaccines and other treatments for medical countermeasures against infectious diseases and biological threats.
“MaxCyte flow electroporation—a clinically proven, cell transfection method—enables accelerated and scalable development of recombinant proteins that could be used to respond to pandemic, biodefense, or seasonal influenza needs,” explained Dr. Karen Donato, Executive Vice President, Global Business Development and Marketing, MaxCyte, Inc. “We are honored to partner with USAMRIID in exploring ways the MaxCyte platform can be used to improve the response to emerging health threats.”
MaxCyte is driving the next generation of cell-based medicines. Its best-in-class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cell-based assays, cellular therapy, genetic engineering, protein and antibody production, and rapid response vaccine development with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information visit /